Publications by authors named "Damayanthi Devineni"

Claim this Profile
A
A Model-Based Meta-Analysis Framework Quantifying Drivers of Placebo Response in Atopic Dermatitis Trials.
Jean C Serrano, John Maringwa, Roel Straetemans, Wouter Willems, Sophia G Liva, Damayanthi Devineni

CPT Pharmacometrics Syst Pharmacol· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical Pharmacology Perspective on Development of Adeno-Associated Virus Vector-Based Retina Gene Therapy.
Jennifer Lynn Ford, Eleni Karatza, Hardik Mody, Prathap Nagaraja Shastri, Sana Khajeh Pour, Damayanthi Devineni

Clin Pharmacol Ther· June 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Author Correction: Preclinical and clinical characterization of the RORγt inhibitor JNJ-61803534.
Xiaohua Xue, Aimee De Leon-Tabaldo, Rosa Luna-Roman, Glenda Castro, Michael Albers, Damayanthi Devineni

Sci Rep· April 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Preclinical and clinical characterization of the RORγt inhibitor JNJ-61803534.
Xiaohua Xue, Aimee De Leon-Tabaldo, Rosa Luna-Roman, Glenda Castro, Michael Albers, Damayanthi Devineni

Sci Rep· May 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Rosuvastatin Myotoxicity After Starting Canagliflozin Treatment.
Rao N V S Mamidi, Damayanthi Devineni, Don Sun, Yshai Yavin, Norman Rosenthal

Ann Intern Med· March 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effect of canagliflozin on the pharmacokinetics of glyburide, metformin, and simvastatin in healthy participants.
Damayanthi Devineni, Prasarn Manitpisitkul, Joseph Murphy, Donna Skee, Ewa Wajs

Clin Pharmacol Drug Dev· January 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Dynamic population pharmacokinetic-pharmacodynamic modelling and simulation supports similar efficacy in glycosylated haemoglobin response with once or twice-daily dosing of canagliflozin.
Willem de Winter, Adrian Dunne, Xavier Woot de Trixhe, Damayanthi Devineni, Chyi-Hung Hsu

Br J Clin Pharmacol· May 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Population Pharmacokinetic Modeling of Canagliflozin in Healthy Volunteers and Patients with Type 2 Diabetes Mellitus.
Eef Hoeben, Willem De Winter, Martine Neyens, Damayanthi Devineni, An Vermeulen

Clin Pharmacokinet· February 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Single-dose Pharmacokinetics and Pharmacodynamics of Canagliflozin, a Selective Inhibitor of Sodium Glucose Cotransporter 2, in Healthy Indian Participants.
Damayanthi Devineni, David Polidori, Christopher Curtin, Hans Stieltjes, Hong Tian

Clin Ther· January 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacodynamic effects of canagliflozin, a sodium glucose co-transporter 2 inhibitor, from a randomized study in patients with type 2 diabetes.
Sue Sha, Damayanthi Devineni, Atalanta Ghosh, David Polidori, Marcus Hompesch

PLoS One· December 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacodynamic effects of canagliflozin, a sodium glucose co-transporter 2 inhibitor, from a randomized study in patients with type 2 diabetes.
Sue Sha, Damayanthi Devineni, Atalanta Ghosh, David Polidori, Marcus Hompesch

PLoS One· October 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical Pharmacokinetic, Pharmacodynamic, and Drug-Drug Interaction Profile of Canagliflozin, a Sodium-Glucose Co-transporter 2 Inhibitor.
Damayanthi Devineni, David Polidori

Clin Pharmacokinet· October 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
In vitro metabolism of canagliflozin in human liver, kidney, intestine microsomes, and recombinant uridine diphosphate glucuronosyltransferases (UGT) and the effect of genetic variability of UGT enzymes on the pharmacokinetics of canagliflozin in humans.
Stephan Francke, Rao N V S Mamidi, Bhavna Solanki, Ellen Scheers, Andrew Jadwin, Damayanthi Devineni

J Clin Pharmacol· September 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacokinetics, Pharmacodynamics, and Safety of Single-Dose Canagliflozin in Healthy Chinese Subjects.
Xia Chen, Pei Hu, Nicole Vaccaro, David Polidori, Christopher R Curtin, Damayanthi Devineni

Clin Ther· July 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effect of food on the pharmacokinetics of canagliflozin, a sodium glucose co-transporter 2 inhibitor, and assessment of dose proportionality in healthy participants.
Damayanthi Devineni, Prasarn Manitpisitkul, Joseph Murphy, Hans Stieltjes, Jay Ariyawansa

Clin Pharmacol Drug Dev· July 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Absolute oral bioavailability and pharmacokinetics of canagliflozin: A microdose study in healthy participants.
Damayanthi Devineni, Joseph Murphy, Shean-Sheng Wang, Hans Stieltjes, Paul Rothenberg

Clin Pharmacol Drug Dev· July 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacokinetics and pharmacodynamics of once- and twice-daily multiple-doses of canagliflozin, a selective inhibitor of sodium glucose co-transporter 2, in healthy participants.
Damayanthi Devineni, David Polidori, Christopher R Curtin, Joseph Murphy, Shean-Sheng Wang

Int J Clin Pharmacol Ther· June 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effect of food on the pharmacokinetics of canagliflozin/metformin (150/1,000 mg) immediate-release fixed-dose combination tablet in healthy participants.
Joseph Murphy, Shean-Sheng Wang, Hans Stieltjes, Ewa Wajs, Damayanthi Devineni

Int J Clin Pharmacol Ther· March 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effect of hepatic or renal impairment on the pharmacokinetics of canagliflozin, a sodium glucose co-transporter 2 inhibitor.
Damayanthi Devineni, Christopher R Curtin, Thomas C Marbury, William Smith, Nicole Vaccaro

Clin Ther· March 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effects of rifampin, cyclosporine A, and probenecid on the pharmacokinetic profile of canagliflozin, a sodium glucose co-transporter 2 inhibitor, in healthy participants.
Damayanthi Devineni, Nicole Vaccaro, Joe Murphy, Christopher Curtin, Rao N V S Mamidi

Int J Clin Pharmacol Ther· February 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Single- and multiple-dose pharmacokinetics and pharmacodynamics of canagliflozin, a selective inhibitor of sodium glucose co-transporter 2, in healthy participants.
Damayanthi Devineni, Nicole Vaccaro, David Polidori, Hans Stieltjes, Ewa Wajs

Int J Clin Pharmacol Ther· February 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effect of canagliflozin, a sodium glucose co-transporter 2 inhibitor, on the pharmacokinetics of oral contraceptives, warfarin, and digoxin in healthy participants.
Damayanthi Devineni, Prasarn Manitpisitkul, Nicole Vaccaro, Apexa Bernard, Donna Skee

Int J Clin Pharmacol Ther· January 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Canagliflozin, a sodium glucose co-transporter 2 inhibitor, reduces post-meal glucose excursion in patients with type 2 diabetes by a non-renal mechanism: results of a randomized trial.
Peter Stein, Jolene K Berg, Linda Morrow, David Polidori, Eunice Artis, Damayanthi Devineni

Metabolism· October 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Metabolism and excretion of canagliflozin in mice, rats, dogs, and humans.
Rao N V S Mamidi, Filip Cuyckens, Jie Chen, Ellen Scheers, Dennis Kalamaridis, Damayanthi Devineni

Drug Metab Dispos· May 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effects of hydrochlorothiazide on the pharmacokinetics, pharmacodynamics, and tolerability of canagliflozin, a sodium glucose co-transporter 2 inhibitor, in healthy participants.
Damayanthi Devineni, Nicole Vaccaro, David Polidori, Sarah Rusch, Ewa Wajs

Clin Ther· May 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis